Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ribavirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | EIF4E | P06730 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TOP1 | P11387 | 1/20 | 1.00 |
| ▸ | PNP | P00491 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribavirin SCHEMBL1981630 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL326516 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL427229 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL14379766 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL41472 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL12758160 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL18537396 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL3954927 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL21311208 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL20806078 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 546 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083840-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | PREC BIOLOGICS INC (US) | 2026-03-26 | — | — | US | claimed |
| CN-119403836-A | Methods for eliminating myeloid-derived suppressor cells using NEO-201 antibodies | 精密生物制品股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| EP-4499710-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | Precision Biologics, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| US-20240400714-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREG CELLS | PREC BIOLOGICS INC (US) | 2024-12-05 | — | — | US | claimed |
| US-20240384003-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | PREC BIOLOGICS INC (US) | 2024-11-21 | — | — | US | claimed |
| US-12037410-B2 | Methods and compositions for targeting Treg cells | PRECISION BIOLOGICS, INC. (US) | 2024-07-16 | — | — | US | claimed |
| EP-4352103-A2 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | Precision Biologics, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| WO-2023225608-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | PRECISION BIOLOGICS, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| WO-2022246066-A2 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | PRECISION BIOLOGICS, INC. (US) | 2022-11-24 | — | — | WO | claimed |
| US-20210002383-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREG CELLS | PREC BIOLOGICS INC (US) | 2021-01-07 | — | — | US | claimed |
| WO-2015143190-A1 | ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2015-09-24 | — | — | WO | claimed |
| EP-2858648-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | Beth Israel Deaconess Medical Center, Inc. (US) | 2015-04-15 | — | — | EP | claimed |
| US-20140219957-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-08-07 | — | — | US | claimed |
| WO-2013185055-A1 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2013-12-12 | — | — | WO | claimed |
| WO-2012162698-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2012-11-29 | — | — | WO | claimed |
| US-20100144618-A1 | Compositions containing an intestinal trefoil peptide and a mucoadhesive | PODOLSKY DANIEL K | 2010-06-10 | — | — | US | claimed |
| US-20090226431-A1 | Treatment of Cancer and Other Diseases | VIANOVA LABS, INC. | 2009-09-10 | — | — | US | claimed |
| US-20060189526-A1 | COMPOSITIONS CONTAINING AN INTESTINAL TREFOIL PEPTIDE AND A MUCOADHESIVE | THE GENERAL HOSPITAL CORPORATION | 2006-08-24 | — | — | US | claimed |
| US-20060188471-A1 | METHODS OF TREATING EPITHELIAL LESIONS | THE GENERAL HOSPITAL CORPORATION | 2006-08-24 | — | — | US | claimed |
| WO-2005004881-A1 | USE OF RIBOFURANOSE DERIVATIVES AGAINST INFLAMMATORY BOWEL DISEASES | ICN PHARMACEUTICALS SWITZERLAND LTD. (CH) | 2005-01-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083840-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | CD47, SIGLEC9, LGALS1 | LMNA 4078/4885SMN1; SMN2 2364/4885ALDH1A1 2065/4885 |
| US-20090226431-A1 | Treatment of Cancer and Other Diseases | CYP46A1, CYP27A1, HMGCR | LMNA 3457/4885SMN1; SMN2 4623/4885ALDH1A1 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.